Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 4734-4738, December 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bryant, B. M.
Right arrow Articles by Smyth, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bryant, B. M.
Right arrow Articles by Smyth, J. F.

Quantification by Gas Chromatography of N,N'-Di-(2-chloroethyl)-phosphorodiamidic Acid in the Plasma of Patients Receiving Isophosphamide1, 2,

Bruce M. Bryant3, Michael Jarman4, Michael H. Baker, Ian E. Smith and John F. Smyth

Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PX, England [B. M. B., M. J., M. H. B., I. E. S.], and The University of Edinburgh, Medical Oncology Unit, The Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, Scotland [J. F. S.]

A sensitive method, based on gas chromatography using a phosphorus-specific flame photometric detector, has been developed for quantifying N,N'-di-(2-chloroethyl)phosphorodiamidic acid (isophosphoramide mustard), the putative active metabolite of isophosphamide, in human plasma. Phosphoramide mustard was used as internal standard, and the two compounds were converted into separable trimethyl derivatives by reaction with methyl iodide in the presence of silver oxide. The chemistry of the derivatization process has been elucidated using gas chromatography-electron impact mass spectrometry and selected ion monitoring. Levels of isophosphamide and of isophosphoramide mustard were measured in the plasma of patients receiving isophosphamide (2 g/sq m). Peak plasma levels of isophosphoramide mustard of 18.6 to 30.3 nmol/ml occurred at 2 to 4 hr, and levels were still appreciable (6.3 to 11.3 nmol/ml) at 24 hr.

1 This investigation was supported by a grant to the Institute of Cancer Research from the Medical Research Council (Grant G973/786).

2 2-(2-Chloroethyl)amino-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide.

3 Gordon Hamilton Fairley Research Training Fellow.

4 To whom requests for reprints should be addressed.

Received 3/18/80. Accepted 8/27/80.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.